DE69826304T2 - Immunoreaktive peptid ctl epitope von menschlichem cytomegalovirus - Google Patents
Immunoreaktive peptid ctl epitope von menschlichem cytomegalovirus Download PDFInfo
- Publication number
- DE69826304T2 DE69826304T2 DE69826304T DE69826304T DE69826304T2 DE 69826304 T2 DE69826304 T2 DE 69826304T2 DE 69826304 T DE69826304 T DE 69826304T DE 69826304 T DE69826304 T DE 69826304T DE 69826304 T2 DE69826304 T2 DE 69826304T2
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- human cytomegalovirus
- lymphocytes
- antigen
- hcmv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 84
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims description 73
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 50
- 229960005486 vaccine Drugs 0.000 claims abstract description 29
- 208000015181 infectious disease Diseases 0.000 claims abstract description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 19
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000013603 viral vector Substances 0.000 claims description 12
- 108091054437 MHC class I family Proteins 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 230000036039 immunity Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 125000003473 lipid group Chemical group 0.000 claims description 6
- 230000000638 stimulation Effects 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 102000043129 MHC class I family Human genes 0.000 claims description 4
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 4
- 241000700618 Vaccinia virus Species 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 230000007420 reactivation Effects 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 208000024697 human cytomegalovirus infection Diseases 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000000899 immune system response Effects 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 6
- 208000032420 Latent Infection Diseases 0.000 claims 1
- 241000287219 Serinus canaria Species 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 26
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract description 9
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 7
- 239000002671 adjuvant Substances 0.000 abstract description 7
- 229920001184 polypeptide Polymers 0.000 abstract description 3
- 241000701022 Cytomegalovirus Species 0.000 abstract description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract description 2
- 230000002163 immunogen Effects 0.000 abstract description 2
- 108010028921 Lipopeptides Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 5
- 229960002963 ganciclovir Drugs 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 3
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108010087302 Viral Structural Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000006648 viral gene expression Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010058854 Cytomegalovirus viraemia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021190 leftovers Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- AWQGSTMURBTWED-FQEVSTJZSA-N n-[(2s)-2,6-diaminohexanoyl]hexadecanamide Chemical group CCCCCCCCCCCCCCCC(=O)NC(=O)[C@@H](N)CCCCN AWQGSTMURBTWED-FQEVSTJZSA-N 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95006497A | 1997-10-14 | 1997-10-14 | |
| US950064 | 1997-10-14 | ||
| US09/021,298 US6156317A (en) | 1996-11-12 | 1998-02-10 | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US21298 | 1998-02-10 | ||
| PCT/US1998/009652 WO1999019349A1 (en) | 1997-10-14 | 1998-05-11 | Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69826304D1 DE69826304D1 (de) | 2004-10-21 |
| DE69826304T2 true DE69826304T2 (de) | 2005-10-20 |
Family
ID=26694530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69826304T Expired - Lifetime DE69826304T2 (de) | 1997-10-14 | 1998-05-11 | Immunoreaktive peptid ctl epitope von menschlichem cytomegalovirus |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6156317A (https=) |
| EP (1) | EP1023319B1 (https=) |
| JP (1) | JP2001519181A (https=) |
| AT (1) | ATE276270T1 (https=) |
| AU (1) | AU7481498A (https=) |
| CA (1) | CA2308118A1 (https=) |
| DE (1) | DE69826304T2 (https=) |
| WO (1) | WO1999019349A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562345B1 (en) | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| DE50016068D1 (de) | 1999-06-04 | 2011-03-24 | Florian Kern | Peptide zur vakzinierung gegen das humane cmv |
| US6632435B1 (en) | 1999-10-20 | 2003-10-14 | City Of Hope | CTL epitope analogs |
| US6835383B2 (en) | 2000-03-23 | 2004-12-28 | City Of Hope | Protein kinase deficient, immunologically active CMVpp65 mutants |
| EP1612217A3 (en) * | 2000-03-27 | 2006-01-18 | City of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| EP1328540B1 (en) | 2000-10-20 | 2005-03-23 | City of Hope | Immunoreactive peptidic ctl epitopes of human cytomegalovirus pp150 |
| US20050221350A1 (en) | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| DE10225139A1 (de) * | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| JP2005535627A (ja) * | 2002-06-25 | 2005-11-24 | シティ・オブ・ホープ | アジュバント不含ペプチド・ワクチン |
| DK2311848T3 (da) * | 2002-12-23 | 2013-10-14 | Vical Inc | Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion |
| US7163685B2 (en) * | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
| US20080138354A1 (en) * | 2006-07-21 | 2008-06-12 | City Of Hope | Cytomegalovirus vaccine |
| WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| EP3620465B1 (en) * | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
| EP3156069B8 (en) | 2008-06-20 | 2020-10-21 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| WO2016209816A1 (en) | 2015-06-26 | 2016-12-29 | Memorial Sloan Kettering Cancer Center | Methods of treating cmv retinitis by t cell therapy |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2020127222A2 (en) | 2018-12-17 | 2020-06-25 | Immudex Aps | Panel comprising borrelia mhc multimers |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP4021493A1 (en) * | 2019-08-29 | 2022-07-06 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | T cell epitopes of hcmv and uses of thereof |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075213A (en) * | 1984-07-27 | 1991-12-24 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
| US5470730A (en) * | 1990-09-28 | 1995-11-28 | Immunex | Method for producing TH -independent cytotoxic T lymphocytes |
| JPH06503719A (ja) * | 1990-09-28 | 1994-04-28 | イムネクス コーポレイション | Ｔ↓ｈ依存性細胞障害性Ｔリンパ球の産生方法 |
| JPH06510799A (ja) * | 1992-06-25 | 1994-12-01 | シティ・オブ・ホープ | サイトメガロウイルスのポリペプチドによる細胞溶解性ｔ−リンパ球の誘導 |
| US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
| US5827642A (en) * | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| DE69728289T2 (de) * | 1996-11-12 | 2005-02-24 | City Of Hope, Duarte | Immunreaktive ctl-peptidepitope von humanem cytomegalovirus |
-
1998
- 1998-02-10 US US09/021,298 patent/US6156317A/en not_active Expired - Lifetime
- 1998-05-11 CA CA002308118A patent/CA2308118A1/en not_active Abandoned
- 1998-05-11 WO PCT/US1998/009652 patent/WO1999019349A1/en not_active Ceased
- 1998-05-11 AU AU74814/98A patent/AU7481498A/en not_active Abandoned
- 1998-05-11 EP EP98922216A patent/EP1023319B1/en not_active Expired - Lifetime
- 1998-05-11 AT AT98922216T patent/ATE276270T1/de not_active IP Right Cessation
- 1998-05-11 DE DE69826304T patent/DE69826304T2/de not_active Expired - Lifetime
- 1998-05-11 JP JP2000515920A patent/JP2001519181A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1023319A1 (en) | 2000-08-02 |
| CA2308118A1 (en) | 1999-04-22 |
| AU7481498A (en) | 1999-05-03 |
| JP2001519181A (ja) | 2001-10-23 |
| ATE276270T1 (de) | 2004-10-15 |
| US6156317A (en) | 2000-12-05 |
| DE69826304D1 (de) | 2004-10-21 |
| WO1999019349A1 (en) | 1999-04-22 |
| EP1023319B1 (en) | 2004-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69826304T2 (de) | Immunoreaktive peptid ctl epitope von menschlichem cytomegalovirus | |
| US6074645A (en) | Immuno-reactive peptide CTL epitopes of human cytomegalovirus | |
| US6726910B2 (en) | Immuno-reactive peptide CTL epitopes of human cytomegalovirus | |
| DE69728289T2 (de) | Immunreaktive ctl-peptidepitope von humanem cytomegalovirus | |
| DE60124918T2 (de) | Kodon-optimierte papillomavirussequenzen | |
| DE68926499T2 (de) | Synthetisches antigen zum bewirken einer anti-hiv-reaktion | |
| DE68929478T2 (de) | Rekombinante CMV-Neutralisierungsproteine | |
| AU2001249243A1 (en) | Immuno-reactive peptide CTL epitopes of human cytomegalovirus | |
| DE69733352T2 (de) | Hla-a2.1 bindende peptide und deren verwendung | |
| DE69232265T2 (de) | Induktion von cytolytischen t-lymphocyten mit polypeptiden des cytomegalievirus | |
| DE60109633T2 (de) | Immunreaktive peptidische ctl-epitope aus dem menschlichen cytomegalovirus pp150 | |
| DE68925660T2 (de) | Peptidfragmente von HIV | |
| JP2003531865A (ja) | Ｄｎａおよびワクシニアウイルスベクターワクチンの組み合わせを用いた免疫原性の改善 | |
| DE69007571T2 (de) | Peptidfragmente von HIV. | |
| DE69624586T2 (de) | Peptidvakzine auf basis von fusionsproteinen mit onkogenanteil | |
| JP5731952B2 (ja) | ヒトサイトメガロウイルスの免疫ー反応性ペプチドｃｔｌエピトープ | |
| Choi et al. | The guinea pig as a relevant preclinical model in the rat race for a vaccine against congenital cytomegalovirus infection | |
| DE102012105193A1 (de) | Stimulation der zellulären Immunantwort gegen das Epstein-Barr-Virus (EBV) | |
| DE60035695T2 (de) | Schutzantigen des epstein-barr-virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |